Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

107.89
BATS BZX Real-Time Price
As of 1:54pm ET
 +0.31 / +0.29%
Today’s Change
26.26
Today|||52-Week Range
109.17
+50.68%
Year-to-Date
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
Apr 20 / Zacks.com - Paid Partner Content
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.
Apr 17 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne
Apr 20 / Zacks.com - Paid Partner Content
Biogen to License Alzheimer Candidate from Bristol-Myers
Apr 17 / Zacks.com - Paid Partner Content
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
Apr 19 / Zacks.com - Paid Partner Content
MiMedx Group (MDXG) Catches Eye: Stock Jumps 8.5% in Session
Apr 17 / Zacks.com - Paid Partner Content
Arena Pharma (ARNA) Down After Underwritten Public Offering
Apr 19 / Zacks.com - Paid Partner Content
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
Apr 13 / Zacks.com - Paid Partner Content
Create an Efficient Portfolio with 5 Top Stocks
Apr 19 / Zacks.com - Paid Partner Content
Roche Launches Antibody Test to Diagnose Prostate Cancer
Apr 13 / Zacks.com - Paid Partner Content
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
Apr 18 / Zacks.com - Paid Partner Content
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe
Apr 13 / Zacks.com - Paid Partner Content
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
Apr 18 / Zacks.com - Paid Partner Content
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
Apr 12 / Zacks.com - Paid Partner Content
Roche's Hemophilia A Drug Positive in Second Phase III Study
Apr 17 / Zacks.com - Paid Partner Content
Pacira Focuses on Lead Candidate Exparel's Label Expansion
Apr 12 / Zacks.com - Paid Partner Content